At Fifteen Months Post-Launch, AbbVie’s Qulipta Outperforms Pfizer’s Nurtec ODT on Perceived Overall Efficacy in the Preventive Migraine Space, According to Spherix Global Insights
Use of Qulipta as a preventive migraine treatment still trails Nurtec ODT, but future projections have the brands’ use on par. Exton, PA., March 16, 2023 – Spherix Global Insights recently released data from their Launch Dynamix™: Qulipta for Migraine Prevention (US) deep dive study tracking the launch of AbbVie’s Qulipta for the preventive treatment […]
The IgA Nephropathy Landscape Has Experienced Rapid Changes Over Past Two Years with Increased Use of SGLT2 Inhibitors and Tarpeyo (Calliditas); More Change on The Way with Filspari (Travere) Launch, According to Spherix Global Insights
Content Area
Early Launch Metrics for TG Therapeutics’ Briumvi in RMS Trail Those of Novartis’ In-Class Competitor Kesimpta, According to Spherix Global Insights
Content Area
Despite Market Access Hurdles and Limited Familiarity Hampering Initial Uptake, Neurologists Project Robust Future Use of Relyvrio for the Treatment of ALS, According to Spherix Global Insights
Recent research suggests Relyvrio will benefit from the limited number of therapies approved to slow decline in ALS Exton, PA., March 9, 2023 – With the FDA approval of Amylyx’s Relyvrio (AMX0035; sodium phenylbutyrate and taurursodiol) for amyotrophic lateral sclerosis (ALS) in September 2022, patients gained access to only the third novel molecule approved for […]
US Neurologists Cautiously Optimistic About Potential Approval of Pfizer’s Zavegepant for the Acute Treatment of Migraine, According to Spherix Global Insights
Recently released positive phase 3 data for Pfizer’s zavegepant likely to fuel already noted perceptions among prescribers that the brand will have a high responder rate. Exton, PA., February 28, 2023 – On February 16, The Lancet Neurology published the Phase 3 results of Pfizer’s zavegepant for the acute treatment of migraine. The CGRP receptor […]
Apellis Ushers in a New Era of Geographic Atrophy Treatment with First Ever Approval, According to Spherix Global Insights
Spherix Global Insights surveyed 85 US ophthalmologists, revealing awareness of Apellis’s newly approved GA therapy, Syfovre is high, as are intentions to trial the agent Exton, PA., February 28, 2023 – Apellis Pharmaceuticals recently made history with the approval of Syfovre (pegcetacoplan) for the treatment for Geographic Atrophy (GA). GA is an advanced form of […]
Spherix Global Insights Continues Coverage of Biogen & Coherus Biosciences’ Ranibizumab Biosimilars, Tracking Uptake and Perceptions of the First Commercially Available Biosimilars to Genentech’s Lucentis
According to a survey of ophthalmologists, in the first six months of biosimilar availability, aided awareness and familiarity are marginal while willingness to prescribe is low. Exton, PA., February 24, 2023 – Last summer, the introduction of biosimilar agents into ophthalmologists’ armamentarium was a big event in the United States medical community. Despite the availability […]
One Year Post-Launch of Argenx’s Vyvgart for gMG, US Neurologists Confused on Best Approach to Treatment Dosing Schedules, According to Spherix Global Insights
Despite early satisfaction with Vyvgart, half of surveyed neurologists & neuromuscular specialists report uncertainty regarding re-dosing after the first treatment cycle Exton, PA., February 24, 2023 – Argenx’s launch of Vyvgart (efgartigimod) has been a success, with global first-year revenue of ~$400 million USD. As the second biologic approved for generalized myasthenia gravis (gMG) and […]
Retina Specialist: Why are ophthalmologists a definite maybe about biosimilars? Survey provides answers
February 14, 2023 Even with the launch of the first two anti-VEGF biosimilars last year, retina specialists seem somewhat ambivalent about using these copy-cat versions of tried and true treatments, a new report based on a survey of ophthalmologists has found. The report, titled “Special Topix: Ophthalmology Biosimilars Today and Tomorrow,” is based on a […]
Declining MS Sales for Historic Powerhouse Biogen Point to Shifting Tides in the Multiple Sclerosis Market According to Spherix Global Insights
U.S. neurologists increasingly favor Novartis’ MS portfolio, particularly Kesimpta Exton, PA., February 17, 2023 – According to Biogen’s earnings call on Wednesday, February 15, 2023, sales for its multiple sclerosis (MS) franchise are down for the third year in a row. The company attributed the 2022 decline to generic erosion, pricing pressures, and a shift […]
